Novel alternatives and supplements to lithium and anticonvulsants for bipolar affective disorder

Journal of Clinical Psychiatry

Volumn 58, Issue 5, 1997, Pages 223-242

  Dubovsky, Steven L ^a,b   Buzan, Randall D ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHLORAL HYDRATE; CHLORPROMAZINE; CLONAZEPAM; CLONIDINE; CLOZAPINE; DEXAMPHETAMINE; DILTIAZEM; FLUNARIZINE; FLUPHENAZINE; GABAPENTIN; LAMOTRIGINE; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; NIFEDIPINE; NIMODIPINE; PARALDEHYDE; RISPERIDONE; SALCATONIN; TEMAZEPAM; THYROID HORMONE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTHYROIDISM; MANIC DEPRESSIVE PSYCHOSIS; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSURGERY; REVIEW; WITHDRAWAL SYNDROME;

EID: 0030902504     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v58n0509     Document Type: Review

References (221)

1. Chou JCY. Recent advances in treatment of acute mania. J Clin Psychopharmacol 1991;11:3-21
2. Keck PE Jr, McElroy SL, Vuckovic A, et al. Combined valproate and carbamazepine treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992;4:319-322
3. Bowden CL, Brugger AM, Swann AC. Efficacy of divalproex vs lithium in the treatment of mania. JAMA 1994;271:918-924
4. Prien RF, Gelenberg AJ. Alternatives to lithium for preventive treatment of bipolar disorder. Am J Psychiatry 1989;146:840-848
5. Post RM. Non-lithium treatment for bipolar disorder. J Clin Psychiatry 1990;51(8, suppl):9-16
6. Small JG, Klapper MH, Kellams JJ. Electroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry 1988;45:727-732
7. Hopkins HS, Gelenberg AJ. Treatment of bipolar disorder: how far have we come? Psychopharmacol Bull 1994;30:27-38
8. Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993;13:397-408
9. Avissar S, Schreiber G. The involvement of guanine nucleotide binding proteins in the pathogenesis and treatment of affective disorders. Biol Psychiatry 1992;31:435-459
10. Avissar S, Schreiber G. Interaction of antibipolar and antidepressant treatments with receptor-coupled G proteins. Pharmacopsychiatry 1992;25:44-50
11. Dubovsky SL, Murphy J, Christiano J, et al. The calcium second messenger system in bipolar disorders: data supporting new research directions. J Neuropsychiatry Clin Neurosci 1992;4:3-14
12. Small JG, Milstein V, Miller MJ, et al. Clinical, neuropsychological, and EEG evidence for mechanisms of action of ECT. Convuls Ther 1988; 4:280-291
13. Maraziti D, Lenzi A, Raffaelli S, et al. A single electroconvulsive treatment affects platelet serotonin uptake in bipolar I patients. Eur Neuropsychopharmacol 1993;3:33-36
14. Post RM. The anticonvulsant connection. Neuropsychopharmacology 1990;3:89-92
15. McCabe MS, Morris B. ECT versus chlorpromazine in mania. Biol Psychiatry 1977;12:245-254
16. Black DW, Winokur G, Nasrallah A Treatment of mania: a naturalistic study of electroconvulsive therapy versus lithium in 438 patients. J Clin Psychiatry 1987;48:132-139
17. Schnur DB, Mukherjee S, Sackeim HA, et al. Symptomatic predictors of ECT response in medication-nonresponsive manic patients. J Clin Psychiatry 1992;53:63-66
18. Mukherjee S, Sackeim HA, Schnur DB. Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. Am J Psychiatry 1994;151:169-176
19. Wehr T, Sack D, Rosenthal N, et al. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988;145:179-184
20. Kutcher S, Robertson HA. Electroconvulsive therapy in treatment-resistant bipolar youth. Journal of Child and Adolescent Psychopharmacology 1995;5:167-175
21. Schneekloth TB, Rummans TA, Logan KM. Electroconvulsive therapy in adolescents. Convuls Ther 1993;9:158-166
22. Bertagnolli MW, Borchardt CM. A review of ECT for children and adolescents. Journal of Child and Adolescent Psychopharmacology 1990; 29:302-307
23. Carr V, Dorrington C, Schrader G, et al. The use of ECT for mania in childhood bipolar disorder. Br J Psychiatry 1983;143:411-415
24. Warnecke L. A case of manic-depressive illness in childhood. Can Psychiatr Assoc J 1975;20:195-200
25. Milstein V, Small JG, Klapper MH. Uni-versus bilateral ECT in the treatment of mania. Convuls Ther 1987;3:1-9
26. Small JG, Small IF, Milstein V. Manic symptoms: an indication for bilateral ECT. Biol Psychiatry 1985;20:125-134
27. Small JG, Klapper MH, Milstein V, et al. Comparison of therapeutic modalities for mania. Psychopharmacol Bull 1996;32:623-627
28. Lamy S, Bergsholm P, d'Elia G. The antidepressant efficacy of high-dose nondominant long-distance parietotemporal and bitemporal electroconvulsive therapy. Convuls Ther 1994;10:43-52
29. McCabe MS. ECT in the treatment of mania: a controlled study. Am J Psychiatry 1976;133:688-691
30. Fink M. Electroconvulsive therapy in children and adolescents. Convuls Ther 1993;9:155-157
31. Bergsholm P, Martinsen EW, Svoen N, et al. Affective disorders: drug treatment and electroconvulsive therapy. Tidsskr Nor Laegeforen 1992; 112:2651-2656
32. Karliner W, Wehrheim HK. Maintenance convulsive treatments. Am J Psychiatry 1965;121:1113-1115
33. Sachs GS. Adjuncts and alternatives to lithium therapy for bipolar affective disorder. J Clin Psychiatry 1989;50(12, suppl):31-39
34. Bigelow LB, Weinberger DR, Wyatt RJ. Synergism of combined lithium-neuroleptic therapy: a double-blind, placebo-controlled case study. Am J Psychiatry 1981;138:81-83
35. Jaffe RL, Rives W, Dubin WR, et al. Problems in maintenance ECT in bipolar disorder: replacement by lithium. Convuls Ther 1991;7:288-294
36. Dubovsky SL, Christiano J, Daniell LC. Increased platelet intracellular calcium concentration in patients with bipolar affective disorders. Arch Gen Psychiatry 1989;46:632-638
37. Dubovsky SL, Lee C, Christiano J. Elevated intracellular calcium ion concentration in bipolar depression. Biol Psychiatry 1991;29:441-450
38. Dubovsky SL, Murphy J, Thomas M. et al. Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients. Am J Psychiatry 1992;149:118-120
39. Tan CH, Javors MA, Seleshi E. Effects of lithium on platelet ionic intracellular calcium concentration in patients with bipolar (manic-depressive) disorder and healthy controls. Life Sci 1990;46:1175-1180
40. Dubovsky SL, Lee C, Christiano J. Lithium decreases platelet intracellular calcium ion concentrations in bipolar patients. Lithium 1991;2: 167-174
41. Dubovsky SL, Thomas M, Hijazi A, et al. Intracellular calcium signalling in peripheral cells of patients with bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci 1994;243:229-234
42. Walden J, Grunze H, Bungmann D, et al. Calcium antagonistic effects of carbamazepine as a mechanism of action in neuropsychiatric disorders: studies in calcium dependent model epilepsies. Eur Neuropsychopharmacol 1992;2:455-462
43. Fox AP, Hirning LD, Mogul DJ, et al. Modulation of calcium channels by neurotransmitters, hormones and second messengers. In: Hurwitz L, Partridge LD, Leach JK, eds. Calcium Channels: Their Properties, Functions, Regulation, and Clinical Relevance. Boca Raton, Fla: CRC Press; 1991:251-263
44. Bigger JT, Hoffman BF. Antiarrhythmic drugs. In: Gilman AG, Rall TW, Nies AS, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY: Pergamon Press: 1991:840-873
45. Murad F. Drugs used for the treatment of angina: organic nitrates, calcium-channel blockers, and β-adrenergic agents. In: Gilman AG, Rall TW, Nies AS, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY: Pergamon Press; 1991: 764-783
46. Kenny BA, Kilpatrick AT, Spedding M. Quantification of the affinity of drugs acting at the calcium channel. In: McCormack JG, Cobbold PH, eds. Cellular Calcium: A Practical Approach. Oxford, England: IRL Press; 1991:267-282
47. deFalco FA, Bartiromo U, Mijello L, et al. Calcium antagonist nimodipine in intractable epilepsy. Epilepsia 1992;33:343-345
48. Post RM, Ketter TA, Pazzaglia PJ, et al. New developments in the use of anticonvulsants as mood stabilizers. Neuropsychobiology 1993;27: 132-137
49. Dubovsky SL, Franks RD, Lifschitz M. Effectiveness of verapamil in the treatment of a manic patient. Am J Psychiatry 1982;139:502-504
50. Brotman AW, Farhadi AM, Gelenberg AJ. Verapamil treatment of acute mania. J Clin Psychiatry 1986;47:136-138
51. Kennedy S, Ozersky S, Robillard M. Refractory bipolar illness may not respond to verapamil. J Clin Psychopharmacol 1986;6:316-317
52. Solomon L, Williamson P. Verapamil in bipolar illness. Can J Psychiatry 1986;31:442-444
53. Dubovsky SL, Franks RD, Schrier D. Phenelzine-induced hypomania: effect of verapamil. Biol Psychiatry 1985;20:1009-1014
54. Jacobsen FM, Sack DA, James SP. Delirium induced by verapamil [letter]. Am J Psychiatry 1987;144:248
55. Patterson JF. Treatment of acute mania with verapamil [letter]. J Clin Psychopharmacol 1987;7:206-207
56. Pollack MH, Rosenbaum JF. Verapamil in the treatment of recurrent unipolar depression. Biol Psychiatry 1987;22:779-782
57. Hullett FJ, Potkin SG, Levy AB, et al. Depression associated with nifedipine-induced calcium channel blockers. Am J Psychiatry 1988; 145:1277-1279
58. Mathis P, Schmitt L, Moron P. Efficacite du verapamil dans les acces maniaques. Encephale 1988;14:127-132
59. Helmuth D, Ljaljevic Z, Ramirez L, et al. Choreoathetosis induced by verapamil and lithium treatment [letter]. J Clin Psychopharmacol 1989; 9:454-455
60. Deicken RF. Verapamil treatment of bipolar depression. J Clin Psychopharmacol 1990;10:148-149
61. Eccleston D, Cole AJ. Calcium-channel blockade and depressive illness. Br J Psychiatry 1990;156:889-891
62. Jacques RM, Cox SJ. Verapamil in major (psychotic) depression. Br J Psychiatry 1991;158:124-125
63. Johnson BA, Cowen PJ. Calcium channel blockade and resistant bipolar depression. Irish Journal of Psychological Medicine 1991;8:50-51
64. Lindelius R, Nilsson CG. Flunarizine as maintenance treatment of a patient with bipolar disorder [letter]. Am J Psychiatry 1992;149:139
65. Kastner T, Friedman DL. Verapamil and valproic acid treatment of prolonged mania. J Am Acad Child Adolesc Psychiatry 1992;31:271-275
66. Goodnick PJ. Verapamil prophylaxis in pregnant women with bipolar disorder [letter]. Am J Psychiatry 1993;150:1560
67. Hoschl C. Verapamil for depression? [letter] Am J Psychiatry 1983; 140:1100
68. Piovan D, Padrini R, Moreolo S, et al. Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment. Ther Drug Monit 1995;17:60-67
69. Carman JSA, Wyatt RJ. Calcium: pacesetting the periodic psychoses. Am J Psychiatry 1979;136:1035-1039
70. Mussini M, Agricola R, Moia GC. A preliminary study on the use of calcitonin in clinical psychopathology. J Int Med Res 1984;12:23-29
71. Giannini AJ, Houser WL, Loiselle RH. Antimanic effects of verapamil. Am J Psychiatry 1984;141:1602-1603
72. Caillard V. Treatment of mania using a calcium antagonist-preliminary trial. Neuropsychobiology 1985;14:23-26
73. Giannini AJ, Loiselle RH, Price WA. Comparison of antimanic efficacy of clonidine and verapamil. J Clin Pharmacol 1985;25:307-308
74. Hoschl C, Blahos J, Kabes J. The use of calcium channel blockers in psychiatry. In: Shagass CE, Josiassen RC, Bridger WH, eds. Biological Psychiatry 1985. New York, NY: Elsevier Science; 1986:330-332
75. Eckmann F. Clinical double-blind study with the calcium antagonist flunarizine in cerebral circulatory disturbances. Arzneimittelforschung 1985;35:1276-1279
76. Dose M, Emrich HM, Cording-Tommel C. Use of calcium antagonists in mania. Psychoneuroendocrinology 1986;11:241-243
77. Dubovsky SL, Franks RD, Allen S, et al. Calcium antagonists in mania: a double-blind study of verapamil. Psychiatry Res 1986;18:309-320
78. Giannini AJ, Taraszewski R, Loiselle RH. Verapamil and lithium as maintenance therapy of manic patients. J Clin Pharmacol 1987;27: 980-982
79. Barton BM, Gitlin MJ. Verapamil in treatment-resistant mania: an open trial. J Clin Psychopharmacol 1987;7:101-103
80. Dinan TG, Silverstone T, Cookson JC. Cortisol, prolactin, and growth hormone levels with clinical ratings in manic patients treated with verapamil. Int Clin Psychopharmacol 1988;3:151-156
81. Kramer MS, Caputo K, DiJohnson C. Negative trial of nifedipine in depression. Biol Psychiatry 1988;4:958-959
82. Hoschl C, Kozemy J. Verapamil in affective disorders: a controlled, double-blind study. Biol Psychiatry 1989;25:128-140
83. Brunet G, Cerlich B, Robert P. Open trial of a calcium antagonist, nimodipine, in acute mania. Clin Neuropharmacol 1990;13:224-228
84. Manna V. Disturbi affectivi bipolari e ruolo del calcio intraneuronale: effetti terapeutici del trattamento con cali di litio e/o calcio antagonista in pazienti con rapida inversione di polarita. Minerva Med 1991;82: 757-763
85. Garza-Trevino ES, Overall JE, Hollister LE. Verapamil versus lithium in acute mania. Am J Psychiatry 1992;149:121-122
86. Pazzaglia PJ, Post RM, Ketter TA, et al. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res 1993;49:257-272
87. Walden J, Fritze J, Van Calker D, et al. A calcium antagonist for the treatment of depressive episodes: single case reports. J Psychiatr Res 1995; 29:71-76
88. Goodnick PJ. Nimodipine treatment of rapid cycling bipolar disorder [letter]. J Clin Psychiatry 1995;56:330
89. Dubovsky SL, Buzan RD. The role of calcium channel blockers in the treatment of psychiatric disorders. CNS Drugs 1995;4:47-57
90. Walton SA, Berk M, Brook S. Superiority of lithium over verapamil in mania: a randomized, controlled, single-blind trial. J Clin Psychiatry 1996;57:543-546
91. Gerber JS, Nies AS. Antihypertensive agents and the drug therapy of hypertension. In: Gilman AG, Rall TW, Nies AS, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY: Pergamon Press; 1991:784-813
92. Dubovsky SL. Calcium channel antagonists as novel agents for manic-depressive disorder. In: Schatzberg AF, Nemeroff CB, eds. American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995:377-388
93. Freedman DD, Waters DD. "Second generation" dihydropyridine calcium antagonists: greater vascular selectivity and some unique applications. Drugs 1987;34:578-598
94. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274:620-625
95. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested [editorial]. JAMA 1995;274:654-655
96. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS): a randomized controlled trial. JAMA 1996;276:785-791
97. Vaage-Nilsen M, Hansen JF, Hagerup L, et al. Effect of verapamil on the prognosis of patients with early postinfarction electrical or mechanical complications: the Danish Verapamil Infarction Trial II (DAVIT II). Int J Cardiol 1995;48:255-258
98. Jespersen CM and The Danish Study Group on Verapamil in Myocardial Infarction. Role of ischemia in postinfarction heart failure: hypothetical considerations based on use of verapamil in the DAVIT II study. Cardiovasc Drugs Ther 1994;8:823-828
99. Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the calcium antagonist reinfarction Italian study (CRIS). Am J Cardiol 1996;77:365-369
100. Jespersen CM, Hansen JF, Mortensen LS, and The Danish Study Group on Verapamil in Myocardial Infarction. The prognostic significance of post-infarction angina pectoris and the effect of verapamil on the incidence of angina pectoris and prognosis. Eur Heart J 1994;15:270-276
101. Hansen JF and the Danish Study Group on Verapamil in Myocardial Infarction. Review of postinfarct treatment with verapamil: combined experience of early and late intervention studies with verapamil in patients with acute myocardial infarction. Cardiovasc Drugs Ther 1994;8(suppl 3):543-547
102. Pahor M, Guralnik JM, Salive ME, et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996;9:695-699
103. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996;348:493-498
104. Alderman MH. More news about calcium antagonists. Am J Hypertens 1996;9:710-712
105. Daling JR. Calcium channel blockers and cancer: is an association biologically plausible? Am J Hypertens 1996;9:713-714
106. ++ concentrations in human tumor cells: possible role in tumor growth. Int J Cancer 1995;62:291-296
107. Taylor JM, Simpson RU. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res 1992;52: 2413-2418
108. Popper LD, Batra S. Calcium mobilization and cell proliferation activated by extracellular ATP in human ovarian tumour cells. Cell Calcium 1993;14:209-218
109. Byerly WG, Hartmann A, Foster DE, et al. Verapamil in the treatment of maternal paroxysmal supraventricular tachycardia. Ann Emerg Med 1991;20:552-554
110. Amery WK, Wauquier A, Van Neuten JM. The anti-migrainous pharmacology of flunarizine (R14 950), a calcium antagonist. Drugs Exp Clin Res 1981;7:1-10
111. Reiter S, Adler R, Angrist B, et al. Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients. J Clin Psychiatry 1989; 50:26-27
112. Walsh TL, Lavenstein B, Licamele WL. Calcium antagonists in the treatment of Tourette's disorder. Am J Psychiatry 1986;143:1467-1468
113. Litzinger M, Nelson PG, Pun RYK. Does nitrendipine block calcium channels in mammalian neurons? implications for treatment of ischemic cell death. Neurology 1985;35(suppl 1):141
114. Yamawaki S, Yanagawa K, Mono M, et al. Possible central effect of dantrolene sodium in neuroleptic malignant syndrome [letter]. J Clin Psychopharmacol 1986;378-379
115. Leys D, Vermersch P, Daniel T. Diltiazem for tardive dyskinesia. Lancet 1988;1:250-251
116. Santillan R, Maestre JM, Hurle MA, et al. Enhancement of opiate analgesia by nimodipine in cancer patients chronically treated with morphine: a preliminary report. Pain 1994;58:129-132
117. Nayler WG. New trends in calcium antagonism: are they meaningful? Am J Hypertens 1994;7:1265-1305
118. Gupta V, Kamath N, Tkalcevic GT, et al. Potentiation of tamoxifen activity by verapamil in a human breast cancer cell line. Biochem Pharmacol 1994;47:1701-1704
119. Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 1992;31:205-213
120. Pereira E, Teodori E, Dei S, et al. Reversal of multidrug resistance by verapamil analogues. Biochem Pharmacol 1995;50:451-457
121. Carbonne B, Jannet D, Touboul C, et al. Nicardipine treatment of hypertension during pregnancy. Obstet Gynecol 1993;81:908-914
122. Wide-Swensson DG, Ingemarsson I, Lunell N, et al. Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study. Am J Obstet Gynecol 1996;173: 872-878
123. Ulmsten U, Anderson KE, Wingerup I. Treatment of premature labor with the calcium antagonist nifedipine. Arch Gynecol Obstet 1980;229: 1-5
124. Kane JM. The role of neuroleptics in manic-depressive illness. J Clin Psychiatry 1988;49(11, suppl):12-13
125. McElroy SL, Keck PE Jr, Strakowski SM. Mania, psychosis, and antipsychotics. J Clin Psychiatry 1996;57(suppl 3):14-26
126. Mikuni M, Meltzer HY. Reduction of serotonin-2 receptors in rat cerebral cortex after incubation with imipramine and chlorpromazine. Life Sci 1984;34:87-92
127. Roy-Byrne PP, Joffe RT, Uhde TW, et al. Approaches to the evaluation and treatment of rapid-cycling affective illness. Br J Psychiatry 1984; 145:543-550
128. Littlejohn R, Leslie F, Cookson J. Depot antipsychotics in the prophylaxis of bipolar affective disorder. Br J Psychiatry 1994;165:827-829
129. Kukopulos A, Reginaldi D, Laddomada P. Course of the manic-depressive cycle and changes caused by treatments. Pharmacopsychiatria 1980: 13:156-157
130. Harrow M, Goldberg JF, Grossman LS. et al. Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990;47: 665-671
131. Sernyak MJ, Woods SW. Chronic neuroleptic use in manic-depressive illness. Psychopharmacol Bull 1993;29:375-381
132. Sernyak MJ, Johnson RM, Pearsall HR, et al. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. Am J Psychiatry 1994;151:133-135
133. Aronson TA, Shukla S, Hoff A. Proposed delusional depression subtypes: preliminary evidence from a retrospective study of phenomenology and treatment course. J Affect Disord 1988;14:69-74
134. Dubovsky SL, Thomas M. Psychotic depression: advances in conceptualization and treatment. Hospital and Community Psychiatry 1992;43: 1189-1198
135. Prien RF, Caffey EM, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Arch Gen Psychiatry 1972;26: 146-153
136. Ahlfors UG, Baastrup PC, Dencker SJ. Flupenthixol decanoate in recurrent manic-depressive illness: a comparison with lithium. Acta Psychiatr Scand 1981;64:226-237
137. Lowe MR. Treatment of rapid cycling affective illness [letter]. Br J Psychiatry 1985;146:558
138. Esparon J, Kolloon J, Naylor GJ. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986;148:723-725
139. Hendrick V, Altschuler LL, Szuba MP. Is there a role for neuroleptics in bipolar depression? J Clin Psychiatry 1994;55:533-535
140. Rifkin A, Doddi S, Karajgi B, et al. Dosage of haloperidol for mania. Br J Psychiatry 1994;165:113-116
141. Miller RJ, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993;34: 713-738
142. Mukherjee S, Rosen AM, Caracci G, et al. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 1986;43:342-346
143. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis: diagnostic criteria for the disorder and its treatment. Schizophr Res 1991;5:21-33
144. Kirkpatrick B, Alphs L, Buchanan RW. The concept of supersensitivity psychosis. J Nerv Ment Dis 1992;180:265-270
145. Witschy JK, Malone GL, Holden LD. Psychosis after neuroleptic withdrawal in a manic-depressive patient. Am J Psychiatry 1984;141: 105-106
146. Steiner W, Laporta M, Chouinard G. Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder. Acta Psychiatr Scand 1990;81:437-440
147. Verghese C, DeLeon J, Nair C, et al. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry 1996;39:135-138
148. Shiovitz TM. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 1996;22:591-595
149. Dubovsky SL. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. J Clin Psychiatry 1994; 55(2, suppl):34-44
150. Tohen M, Zarate CA Jr, Centorrino F, et al. Risperidone in the treatment of mania [abstract]. Psychopharmacol Bull 1996;31:626
151. Sajatovic M. A pilot study evaluating the efficacy of risperidone in treatment-refractory, acute bipolar, and schizoaffective mania [abstract]. Psychopharmacol Bull 1996;31:613
152. Zarate CA Jr, Tohen M, Banov MD, et al. Is clozapine a mood stabilizer? J Clin Psychiatry 1995;56:108-112
153. McElroy SL, Dessain EC, Pope HG Jr, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991;52:411-414
154. Suppes T, McElroy SL, Gilbert J, et al. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992;32:270-280
155. Calabrese JR, Meltzer HY, Markovitz PJ. Clozapine prophylaxis in rapid cycling bipolar disorder. J Clin Psychopharmacol 1991;11:396-397
156. Suppes T, Phillips KA, Judd CR. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases. Biol Psychiatry 1994;36:338-340
157. Banov MD, Zarate CA Jr, Tohen M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994;55:295-300
158. Singh AN, Catalan J. Risperidone in HIV-related manic psychosis. Lancet 1994;344:1029-1030
159. Dwight MM, Keck PE Jr, Stanton SP, et al. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet 1994;344:554-555
160. Privitera MR, Lamberti JS, Maharaj K. Clozapine in a bipolar depressed patient [letter]. Am J Psychiatry 1993;150:986
161. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759-764
162. Tohen M, Zarate CA Jr, Centorrino F, et al. Risperidone in the treatment of mania. J Clin Psychiatry 1996;57:249-253
163. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995;56:514-518
164. Sajatovic M, DiGiovanni SK, Bastani B, et al. Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania. Psychopharmacol Bull 1996;32:55-61
165. Schaffer CB, Schaffer LC. The use of risperidone in the treatment of bipolar disorder [letter]. J Clin Psychiatry 1996;57:136
166. Koek RJ, Kessler CC. Probable induction of mania by risperidone [letter]. J Clin Psychiatry 1996;57:174
167. Frye M, Altschuler LL, Bitran IE. Clozapine in rapid cycling bipolar disorder [letter]. J Clin Psychopharmacol 1996;16:87-90
168. Klapheke MM. Clozapine, ECT and schizoaffective disorder, bipolar type. Convuls Ther 1991;7:36-39
169. Keck PE Jr, McElroy SL, Strakowski SM, et al. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. J Clin Psychiatry 1996;57:147-151
170. Moore NA, Tye NC, Axton MS, et al. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992;262:545-551
171. Chouinard G, Young SN, Annable L. Antimanic effect of clonazepam. Biol Psychiatry 1983;18:451-466
172. Pande AC. Clonazepam treatment of atypical bipolar disorder. Psychosomatics 1988;29:333-335
173. Lerer B. Alternative therapies for bipolar disorder. J Clin Psychiatry 1985;46:309-316
174. Nowlin-Finch NL, Altschuler LL, Szuba MP, et al. Rapid resolution of first episodes of mania: sleep related. J Clin Psychiatry 1994;55:26-29
175. Lenox RH, Modell JG, Weiner S. Acute treatment of manic agitation with lorazepam. Psychosomatics 1986;27(suppl):28-31
176. Modell JG, Lenox RH, Weiner S. Inpatient clinical trial of lorazepam for the management of manic agitation. J Clin Psychopharmacol 1985;5: 109-113
177. Bradwejn J, Shriqui C, Kosczvcki D, et al. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol 1990;10:403-408
178. Busch FN, Miller FT, Weiden PJ. A comparison of two adjunctive treatment strategies in acute mania. J Clin Psychiatry 1989;50:453-455
179. Aronson TA, Shukla S, Hirschowitz J. Clonazepam treatment of five lithium-refractory patients with bipolar disorder. Am J Psychiatry 1989;146:77-80
180. Colwell BL, Lopez JR. Clonazepam in mania. Drug Intelligence and Clinical Pharmacy 1987;21:794-795
181. Santos AB, Morton WA. More on clonazepam in manic agitation. J Clin Psychopharmacol 1987;7:439-440
182. Freinhar JP, Alvarez WA. Use of clonazepam in two cases of acute mania. J Clin Psychiatry 1985;46:29-30
183. Victor BS, Link NA, Binder RL, et al. Use of clonazepam in mania and schizoaffective disorders. Am J Psychiatry 1984;141:1111-1112
184. Garza-Trevino ES, Hollister LE, Overall JE, et al. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 1989;146:1598-1601
185. Salzman C, Green AI, Rodriguez-Villa F, et al. Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. Psychosomatics 1986;27(suppl):17-21
186. Post RM. Prophylaxis of bipolar affective disorders. International Review of Psychiatry 1990;2:277-320
187. Cowdry RW, Wehr TA, Zis AP, et al. Thyroid abnormalities associated with rapid-cycling bipolar illness. Arch Gen Psychiatry 1983;40:414-420
188. Extein I, Pottash ALC, Gold MS. Does subclinical hypothyroidism predispose to tricyclic-induced rapid mood cycles? J Clin Psychiatry 1982; 43:290-291
189. Stancer HC, Persad E. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine clinical observations. Arch Gen Psychiatry 1982;39:311-312
190. Bernstein L. Abrupt cessation of rapid-cycling bipolar disorder with the addition of low-dose L-tetraiodothyronine to lithium. J Clin Psychopharmacol 1992;12:443-144
191. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder, II: treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990;47:435-440
192. Bauer MS, Whybrow PC. The effect of changing thyroid function on cyclic affective illness in a human subject. Am J Psychiatry 1986;143: 633-636
193. Bauer MS, Whybrow PC, Winokur A. Rapid-cycling bipolar affective disorder, I: association with grade I hypothyroidism. Arch Gen Psychiatry 1990;47:427-432
194. Extein I, Pottash ALC, Gold MS. Thyroid tests as predictors of treatment response and prognosis in psychiatry. Psychiatric Hospital 1985;16: 127-130
195. Gjessing LR. Disturbances of somatic function in catatonia with a periodic course and their compensation. J Ment Sci 1938;84:608-621
196. Von Hofmann G, Golen H. Therapieversuche bei chronischen Verlaufsforrnen des manisch-depressiven Krankheitsegeschehens (MDK). Arzneimittelforschung 1969;19:455-456
197. Post RM. Approaches to treatment-resistant bipolar affectively ill patients. Clin Neuropharmacol 1988;11:93-104
198. Snaith RP. Psychosurgery: controversy and enquiry. Br J Psychiatry 1994;165:582-584
199. Bridges PK, Bartlett JR, Hale AS, et al. Psychosurgery: stereotactic subcaudate tractotomy: an indispensable treatment. Br J Psychiatry 1994; 165:599-611
200. Poynton A, Bridges PK, Bartlett JR, et al. Resistant bipolar affective disorder treated by stereotactic subcaudate tractotomy: outcome in bipolar affective disorder after stereotactic tractotomy. Br J Psychiatry 1987; 151:113-116
201. Lovett LM, Shaw DM. Outcome in bipolar affective disorder after stereotactic tractotomy. Br J Psychiatry 1987;151:117-121
202. Mattson RH. Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia 1995;36(suppl 2):S13-S26
203. Messenheimer JA. Lamotrigine. Epilepsia 1995;36(suppl 2):S87-S94
204. McLean MJ. Gabapentin. Epilepsia 1995;36(suppl 2):S73-S86
205. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312-322
206. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin) binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271:5768-5776
207. Calabrese JR, Fatemi SH, Woyshville MJ. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder [letter]. Am J Psychiatry 1996;153:1236
208. Anderson GD, Yau MK, Gidal BE, et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996; 60:145-156
209. Matsuo F, Madsen J, Tolman KG, et al. Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study. Epilepsia 1996;37:857-862
210. Beydoun A, Uthman BM, Sackellares JC. Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol 1995;18:469-481
211. Morris GL. Efficacy and tolerability of gabapentin in clinical practice. Clin Ther 1995;17:891-900
212. Sterker M, Berroushot J, Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol Ther 1995;33:595-597
213. Reeves AL, So EL, Sharborough FW, et al. Movement disorders associated with the use of gabapentin. Epilepsia 1996;37:988-990
214. Hauck A, Bhaumik S. Hypomania induced by gabapentin [letter]. Br J Psychiatry 1995;167:549
215. Tallian KB, Nahata MC, Lo W, et al. Gabapentin associated with aggressive behavior in pediatric patients with seizures. Epilepsia 1996;37: 501-502
216. Lee DO, Steingard RJ, Cesena M, et al. Behavioral side effects of gabapentin in children. Epilepsia 1996;37:87-90
217. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36(suppl 2):S2-S12
218. Shuaib A, Mahmood RH, Wishart T, et al. Neuroprotective effects of lamotrigine in global ischemia in gerbils: a histological, in vivo microdialysis and behavioral study. Brain Res 1995;702:199-206
219. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 1996;12:56-58
220. Kahn D. The psychotherapy of mania. Psychiatr Clin North Am 1996; 13:229-240
221. Brady KT, Lydiard RB. Bipolar affective disorder and substance abuse. J Clin Psychopharmacol 1992;12(suppl 1):17S-22S